The drugs that are widely used in LC immunotherapy include medications targeting programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA4), such as Nivolumab and Ipilimumab7. The gene discussed is PDCD1; the disease is laryngotracheoesophageal cleft.